HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV

July 1, 2024

https://www.globenewswire.com/news-release/2024/07/01/2907081/0/en/HOOKIPA-Pharma-Announces-First-Person-Dosed-in-Phase-1b-Clinical-Trial-of-HB-500-for-the-Treatment-of-HIV.html

NEW YORK and VIENNA, July 01, 2024 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ:HOOK, HOOKIPA), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the first person has been dosed in a Phase 1b clinical trial of HB-500, an investigational therapeutic vaccine for the treatment of HIV. As a result, HOOKIPA achieves a $5 million non-dilutive milestone payment under its collaboration and license agreement with Gilead.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.